Skip to main content
Erschienen in: Current Colorectal Cancer Reports 5/2015

01.10.2015 | Therapeutic Approaches to Metastatic Colorectal Cancers (L Vecchione, Section Editor)

“The Role of Primary Tumor Resection (PTR) in Metastatic Colorectal Cancer”

verfasst von: Ravit Geva, Hagit Tulchinsky

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Patients with unresectable metastatic colorectal cancer can either receive systemic chemotherapy as first treatment or have a palliative resection of the primary tumor or endoscopic placement of a self-expanding metallic stent if they present with colonic obstruction. The ongoing dilemma is whether resection of the primary tumor in asymptomatic patients is beneficial. The effectiveness of current systemic treatment regimens on the primary tumor as well as the survival benefit of primary tumor resection in the era of new chemotherapy agents, biologics, and targeted therapy is underreported. No prospective randomized studies have yet been published; nevertheless, based on the available literature, it seems that primary tumor (PTR) can possibly improve short- and long-term outcome in highly selected patients with favorable characteristics, specifically low tumor burden and good performance status.
Literatur
1.
Zurück zum Zitat Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.CrossRefPubMed Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.CrossRefPubMed
2.
Zurück zum Zitat Van Cutsem E et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1–9.CrossRefPubMed Van Cutsem E et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1–9.CrossRefPubMed
4.•
Zurück zum Zitat Shahid Ahmed, P.P., Selliah Kanthan, Anthony L.A. Fields, Duc Minh Le, Kamal Haider, Bruce Reeder, Osama Ahmed, Riaz Alvi, Nayyer Iqbal, Tahir Abbas, Adnan Zaidi, Florence Arnold, Sunil Yadav, Amer Sami, Anne Leis. Surgical management of the primary tumor in stage IV colorectal cancer: A validation study. in 2015 Gastrointestinal Cancers Symposium. A large cohort analyzing PTR on top of modern combination chemotherapy. Shahid Ahmed, P.P., Selliah Kanthan, Anthony L.A. Fields, Duc Minh Le, Kamal Haider, Bruce Reeder, Osama Ahmed, Riaz Alvi, Nayyer Iqbal, Tahir Abbas, Adnan Zaidi, Florence Arnold, Sunil Yadav, Amer Sami, Anne Leis. Surgical management of the primary tumor in stage IV colorectal cancer: A validation study. in 2015 Gastrointestinal Cancers Symposium. A large cohort analyzing PTR on top of modern combination chemotherapy.
5.••
Zurück zum Zitat Aaron Lewis, R.A.N., Lily L. Lai. Resection of primary tumor in patients who present with stage IV colon cancer may result in improved survival. in 2015 Gastrointestinal Cancers Symposium. Summarizes SEER data on PTR with matched controllers. Aaron Lewis, R.A.N., Lily L. Lai. Resection of primary tumor in patients who present with stage IV colon cancer may result in improved survival. in 2015 Gastrointestinal Cancers Symposium. Summarizes SEER data on PTR with matched controllers.
6.••
Zurück zum Zitat Zeinab Alawadi, U.P., Chung-Yuan Hu, Christina Edwards Bailey, Lillian Kao, Y. Nancy You, George J. Chang. Comparative effectiveness of primary tumor resection in metastatic colon cancer: An instrumental variable analysis. in 2015 Gastrointestinal Cancers Symposium. Summarizes PTR effect on a large cohort from the MD Anderson Cancer Center registry with advanced statistics. Zeinab Alawadi, U.P., Chung-Yuan Hu, Christina Edwards Bailey, Lillian Kao, Y. Nancy You, George J. Chang. Comparative effectiveness of primary tumor resection in metastatic colon cancer: An instrumental variable analysis. in 2015 Gastrointestinal Cancers Symposium. Summarizes PTR effect on a large cohort from the MD Anderson Cancer Center registry with advanced statistics.
7.
Zurück zum Zitat Rapiti E et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24(18):2743–9.CrossRefPubMed Rapiti E et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24(18):2743–9.CrossRefPubMed
8.
9.
Zurück zum Zitat Kulig P et al. Non-curative gastrectomy for metastatic gastric cancer: rationale and long-term outcome in multicenter settings. Eur J Surg Oncol. 2012;38(6):490–6.CrossRefPubMed Kulig P et al. Non-curative gastrectomy for metastatic gastric cancer: rationale and long-term outcome in multicenter settings. Eur J Surg Oncol. 2012;38(6):490–6.CrossRefPubMed
11.
Zurück zum Zitat Flanigan RC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.CrossRefPubMed Flanigan RC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.CrossRefPubMed
12.
Zurück zum Zitat Mickisch GH et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.CrossRefPubMed Mickisch GH et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.CrossRefPubMed
13.
Zurück zum Zitat Al-Sanea N, Isbister WH. Is palliative resection of the primary tumour, in the presence of advanced rectal cancer, a safe and useful technique for symptom control? ANZ J Surg. 2004;74(4):229–32.CrossRefPubMed Al-Sanea N, Isbister WH. Is palliative resection of the primary tumour, in the presence of advanced rectal cancer, a safe and useful technique for symptom control? ANZ J Surg. 2004;74(4):229–32.CrossRefPubMed
14.
Zurück zum Zitat Kuo LJ et al. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum. 2003;46(12):1646–52.CrossRefPubMed Kuo LJ et al. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum. 2003;46(12):1646–52.CrossRefPubMed
15.
Zurück zum Zitat Vibert E et al. Multivariate analysis of predictive factors for early postoperative death after colorectal surgery in patients with colorectal cancer and synchronous unresectable liver metastases. Dis Colon Rectum. 2007;50(11):1776–82.CrossRefPubMed Vibert E et al. Multivariate analysis of predictive factors for early postoperative death after colorectal surgery in patients with colorectal cancer and synchronous unresectable liver metastases. Dis Colon Rectum. 2007;50(11):1776–82.CrossRefPubMed
16.
Zurück zum Zitat Takahashi, H., et al., Self-expanding metallic stents versus surgical intervention as palliative therapy for obstructive colorectal cancer: a meta-analysis. World J Surg, 2015. Takahashi, H., et al., Self-expanding metallic stents versus surgical intervention as palliative therapy for obstructive colorectal cancer: a meta-analysis. World J Surg, 2015.
17.
Zurück zum Zitat Deans GT, Krukowski ZH, Irwin ST. Malignant obstruction of the left colon. Br J Surg. 1994;81(9):1270–6.CrossRefPubMed Deans GT, Krukowski ZH, Irwin ST. Malignant obstruction of the left colon. Br J Surg. 1994;81(9):1270–6.CrossRefPubMed
18.
Zurück zum Zitat Costi R et al. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol. 2007;14(9):2567–76.CrossRefPubMed Costi R et al. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol. 2007;14(9):2567–76.CrossRefPubMed
19.
Zurück zum Zitat Sorbye H et al. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol. 2007;18(10):1666–72.CrossRefPubMed Sorbye H et al. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol. 2007;18(10):1666–72.CrossRefPubMed
20.
Zurück zum Zitat Dohmoto M, Rupp KD, Hohlbach G. Endoscopically-implanted prosthesis in rectal carcinoma. Dtsch Med Wochenschr. 1990;115(23):915.PubMed Dohmoto M, Rupp KD, Hohlbach G. Endoscopically-implanted prosthesis in rectal carcinoma. Dtsch Med Wochenschr. 1990;115(23):915.PubMed
21.
Zurück zum Zitat Tack J, Gevers AM, Rutgeerts P. Self-expandable metallic stents in the palliation of rectosigmoidal carcinoma: a follow-up study. Gastrointest Endosc. 1998;48(3):267–71.CrossRefPubMed Tack J, Gevers AM, Rutgeerts P. Self-expandable metallic stents in the palliation of rectosigmoidal carcinoma: a follow-up study. Gastrointest Endosc. 1998;48(3):267–71.CrossRefPubMed
22.
Zurück zum Zitat Camunez F et al. Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology. 2000;216(2):492–7.CrossRefPubMed Camunez F et al. Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology. 2000;216(2):492–7.CrossRefPubMed
23.
Zurück zum Zitat de Gregorio MA et al. Acute colorectal obstruction: stent placement for palliative treatment—results of a multicenter study. Radiology. 1998;209(1):117–20.CrossRefPubMed de Gregorio MA et al. Acute colorectal obstruction: stent placement for palliative treatment—results of a multicenter study. Radiology. 1998;209(1):117–20.CrossRefPubMed
24.
Zurück zum Zitat Souglakos J et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94(6):798–805.PubMedCentralCrossRefPubMed Souglakos J et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94(6):798–805.PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Saltz LB et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.CrossRefPubMed Saltz LB et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.CrossRefPubMed
26.
Zurück zum Zitat Van Cutsem E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMed Van Cutsem E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMed
27.
Zurück zum Zitat Heinemann, V., et al., FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet Oncology. 15(10): p. 1065–1075. Heinemann, V., et al., FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet Oncology. 15(10): p. 1065–1075.
28.
Zurück zum Zitat Alan P. Venook, D.N., Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, Bert H. O'Neil, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles David Blanke, Cancer and Leukemia Group B (Alliance), SWOG, and ECOG. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). in 14 ASCO Annual Meeting Alan P. Venook, D.N., Heinz-Josef Lenz, Federico Innocenti, Michelle R. Mahoney, Bert H. O'Neil, James Edward Shaw, Blase N. Polite, Howard S. Hochster, James Norman Atkins, Richard M. Goldberg, Robert J. Mayer, Richard L. Schilsky, Monica M. Bertagnolli, Charles David Blanke, Cancer and Leukemia Group B (Alliance), SWOG, and ECOG. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). in 14 ASCO Annual Meeting
29.
Zurück zum Zitat Folprecht G et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47.CrossRefPubMed Folprecht G et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47.CrossRefPubMed
30.
Zurück zum Zitat A. Cercek, M.R.W., K. A. Goodman, D. L. Reidy, W. D. Wong, J. G. Guillem, L. K. Temple, D. Schrag, P. Paty, L. Saltz. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. in 2010 ASCO Annual Meeting A. Cercek, M.R.W., K. A. Goodman, D. L. Reidy, W. D. Wong, J. G. Guillem, L. K. Temple, D. Schrag, P. Paty, L. Saltz. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. in 2010 ASCO Annual Meeting
31.
Zurück zum Zitat Gerard, J.P., et al., Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol, 2015. Gerard, J.P., et al., Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol, 2015.
32.
Zurück zum Zitat Fernandez-Martos C et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859–65.CrossRefPubMed Fernandez-Martos C et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859–65.CrossRefPubMed
33.
Zurück zum Zitat M. S. Roh, G.A.Y., M. J. O'Connell, R. W. Beart, H. C. Pitot, A. F. Shields, D. S. Parda, S. Sharif, C. J. Allegra, N. J. Petrelli, J. C. Landry, D. P. Ryan, A. Arora, T. L. Evans, G. S. Soori, L. Chu, R. V. Landes, M. Mohiuddin, S. Lopa, N. Wolmark. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. in 2011 ASCO Annual Meeting M. S. Roh, G.A.Y., M. J. O'Connell, R. W. Beart, H. C. Pitot, A. F. Shields, D. S. Parda, S. Sharif, C. J. Allegra, N. J. Petrelli, J. C. Landry, D. P. Ryan, A. Arora, T. L. Evans, G. S. Soori, L. Chu, R. V. Landes, M. Mohiuddin, S. Lopa, N. Wolmark. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. in 2011 ASCO Annual Meeting
34.
Zurück zum Zitat Chua YJ et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(3):241–8.CrossRefPubMed Chua YJ et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(3):241–8.CrossRefPubMed
35.
Zurück zum Zitat Uehara K et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43(10):964–71.CrossRefPubMed Uehara K et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43(10):964–71.CrossRefPubMed
36.
Zurück zum Zitat Ruo L et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196(5):722–8.CrossRefPubMed Ruo L et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196(5):722–8.CrossRefPubMed
37.
Zurück zum Zitat Anwar S et al. Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review. Colorectal Dis. 2012;14(8):920–30.CrossRefPubMed Anwar S et al. Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review. Colorectal Dis. 2012;14(8):920–30.CrossRefPubMed
38.
Zurück zum Zitat Cirocchi R et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev. 2012;8, CD008997.PubMed Cirocchi R et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev. 2012;8, CD008997.PubMed
39.
Zurück zum Zitat Ahmed S et al. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study. Cancer. 2014;120(5):683–91.CrossRefPubMed Ahmed S et al. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study. Cancer. 2014;120(5):683–91.CrossRefPubMed
40.
Zurück zum Zitat Lam-Boer J et al. The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer—a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer. 2014;14:741.PubMedCentralCrossRefPubMed Lam-Boer J et al. The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer—a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer. 2014;14:741.PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Rahbari NN et al. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS—a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer. 2012;12:142.PubMedCentralCrossRefPubMed Rahbari NN et al. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS—a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer. 2012;12:142.PubMedCentralCrossRefPubMed
42.
Zurück zum Zitat Poultsides GA et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379–84.PubMedCentralCrossRefPubMed Poultsides GA et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379–84.PubMedCentralCrossRefPubMed
43.
Zurück zum Zitat Tebbutt NC et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52(4):568–73.PubMedCentralCrossRefPubMed Tebbutt NC et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52(4):568–73.PubMedCentralCrossRefPubMed
44.
Zurück zum Zitat D. Schrag, M.R.W., K. A. Goodman, D. L. Reidy, A. Cercek, M. Gonen, W. D. Wong, L. K. Temple, P. Paty, L. Saltz. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. in 2010 Gastrointestinal Cancers Symposium D. Schrag, M.R.W., K. A. Goodman, D. L. Reidy, A. Cercek, M. Gonen, W. D. Wong, L. K. Temple, P. Paty, L. Saltz. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. in 2010 Gastrointestinal Cancers Symposium
45.
Zurück zum Zitat Carlos Fernandez-Martos, R.E., Antonia Salud, Carles Pericay, Manuel Gallen, Enrique Sierra, Javier Serra, Miguel Pera, Juan Maurel, Salvadora Delgado, M. José Safont, Jose Vicente Roig, Jorge Aparicio, Jaime Feliu, Damian Garcia, Ruth Vera, Javier Suarez, Vicente Alonso, Marta Martin-Richard, Gina Brown. Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. in 2012 ASCO Annual Meeting Carlos Fernandez-Martos, R.E., Antonia Salud, Carles Pericay, Manuel Gallen, Enrique Sierra, Javier Serra, Miguel Pera, Juan Maurel, Salvadora Delgado, M. José Safont, Jose Vicente Roig, Jorge Aparicio, Jaime Feliu, Damian Garcia, Ruth Vera, Javier Suarez, Vicente Alonso, Marta Martin-Richard, Gina Brown. Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. in 2012 ASCO Annual Meeting
Metadaten
Titel
“The Role of Primary Tumor Resection (PTR) in Metastatic Colorectal Cancer”
verfasst von
Ravit Geva
Hagit Tulchinsky
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 5/2015
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-015-0281-6

Weitere Artikel der Ausgabe 5/2015

Current Colorectal Cancer Reports 5/2015 Zur Ausgabe

Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)

Local Therapy Options for Oligometastatic Disease in the Liver

Therapeutic Approaches to Metastatic Colorectal Cancers (L Vecchione, Section Editor)

Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?

Translational Colorectal Oncology (Y Jiang, Section Editor)

Distinctive Tumor Biology of MSI-High Colorectal Cancer

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.